Loading patent…
AssigneeNeuvogen, Inc.
InventorsBernadette Ferraro, Justin James Arndt, Todd Merrill Binder, Matthias Hundt, Amritha Balakrishnan Lewis, Kendall M. Mohler, Daniel Lee Shawler, Jian Yan, Mark Bagarazzi
Estimating the term…
The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to acquired tyrosine kinase inhibitor (TKI) resistance mutations, EGFR activating mutations, and/or (v) express modified ALK intracellular domain(s), and/or express one or more driver mutations. Also provided herein are methods of making and preparing the vaccine compositions and methods of use thereof.
A composition comprising a therapeutically effective amount of at least 1 modified cancer cell line, wherein the cell line or a combination of the cell lines comprises cells that express at least 5 tumor associated antigens (TAAs) associated with a cancer of a subject intended to receive said composition, and wherein said composition is capable of eliciting an immune response specific to the at least 5 TAAs, and wherein the cell line or combination of the cell lines have been modified to express at least 1 peptide comprising at least 1 oncogene driver mutation.
-4. (canceled)
(canceled)
-11. (canceled)
-15. (canceled)
-43. (canceled)
A composition comprising cancer cell line NCI-H460, wherein the NCI-H460 cell line is modified in vitro to (i) express at least one immunostimulatory factor, at least one TAA that is either not expressed or minimally expressed by NCI-H460, and at least 1 peptide comprising at least 1 oncogene driver mutation;
(canceled)
A composition comprising cancer cell line A549, wherein the A549 cell line is modified in vitro to (i) express at least one immunostimulatory factor, at least one TAA that is either not expressed or minimally expressed by A549, at least 1 peptide comprising at least 1 oncogene driver mutation, and at least 1 EGFR activating mutation;
(canceled)
A composition comprising cancer cell line NCI-H520, wherein the NCI-H520 cell line is modified in vitro to (i) express at least one immunostimulatory factor;
(canceled)
A composition comprising cancer cell line NCI-H23, wherein the NCI-H23 cell line is modified in vitro to (i) express at least one immunostimulatory factor, at least one TAA that is either not expressed or minimally expressed by NCI-H23, at least 1 EGFR acquired mutation, at least 1 ALK acquired resistance mutation, and ALK-IC;
-53. (canceled)
A composition comprising cancer cell line DMS 53, wherein the DMS 53 cell line is modified in vitro to (i) express at least one immunostimulatory factor;
-61. (canceled)
(canceled)
A unit dose of a medicament for treating cancer comprising at least 5 compositions of different cancer cell lines, wherein each cell line is modified to (i) express or increase expression of at least 2 immunostimulatory factors, (ii) inhibit or decrease expression of at least 2 immunosuppressive factors, and/or (iii) increase expression of at least 1 TAA that are either not expressed or minimally expressed by the cancer cell lines, and/or (iv) express at least 1 peptide comprising at least 1 oncogene driver mutation.
-72. (canceled)
A method of preparing a composition comprising a modified cancer cell line, said method comprising the steps of:
-115. (canceled)
A method of stimulating an immune response in a patient comprising administering to said patient a therapeutically effective amount of a unit dose of a cancer vaccine, wherein said unit dose comprises a composition comprising a cancer stem cell line and at least 3 compositions each comprising a different modified cancer cell line;
A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a unit dose of a cancer vaccine, wherein said unit dose comprises a composition comprising a cancer stem cell line and at least 3 compositions each comprising a different modified cancer cell line;
-132. (canceled)
A composition comprising cancer cell line NCI-H1703, wherein the NCI-H1703 cell line is modified in vitro to (i) express at least one immunostimulatory factor;
Dependencies are inferred from the claim text.